Skip to main content
Clinical Trials/NCT07556965
NCT07556965
Not yet recruiting
Not Applicable

Effect of an Exercise- and Mindfulness-Based Cognitive Therapy Intervention on Physical and Psychological Symptoms in Cancer Patients With Chemotherapy-Induced Peripheral Neuropathy

Nanjing Medical University0 sites40 target enrollmentStarted: April 20, 2026Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Nanjing Medical University
Enrollment
40
Primary Endpoint
Severity of physical symptoms and degree of psychological distress in chemotherapy-induced peripheral neuropathy.

Overview

Brief Summary

The goal of this clinical trial is to learn whether an exercise- and mindfulness-based cognitive therapy intervention can improve physical and psychological symptoms in cancer patients with chemotherapy-induced peripheral neuropathy. It will also examine whether this intervention can improve quality of life. The main questions it aims to answer are:

Can this intervention reduce physical symptoms related to chemotherapy-induced peripheral neuropathy? Can this intervention reduce psychological symptoms in affected patients? Can this intervention improve patients' quality of life?

Participants will:

Follow a structured program of regular exercise and mindfulness practice Undergo weekly assessments of symptom changes Keep records of their symptom changes during the intervention period

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Sequential
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with a pathologically confirmed malignant tumor;
  • Currently receiving neurotoxic chemotherapy and experiencing chemotherapy-induced peripheral neuropathy (CIPN);
  • Cancer stage Tis or stage I-III;
  • Aged 18 years or older, with normal consciousness, mental status, and verbal communication ability; able to understand and judge their own sensations and general condition; and able to complete the questionnaires;
  • Willing to participate in the study and able to provide written informed consent;
  • Patients with NCI-CTCAE grade \<2 who are considered suitable for exercise intervention.

Exclusion Criteria

  • Presence of other neurological diseases or severe psychiatric disorders;
  • Presence of other serious illnesses, such as severe heart disease or respiratory failure;
  • Inability to understand or complete the questionnaires;
  • Participation in psychological counseling, psychotherapy, or other clinical trials within the past 6 months;
  • Inability or expected inability to complete the full 6-week intervention.

Arms & Interventions

Routine nursing.

Experimental

The intervention group will receive an exercise- and mindfulness-based cognitive therapy program. Exercise training will include aerobic exercise and resistance training, conducted 3-5 times per week for 20-30 minutes per session. Mindfulness practice will include mindfulness breathing, body scan, and mindful walking, conducted daily for 10-15 minutes per session.

Intervention: Exercise and Mindfulness (Behavioral)

Outcomes

Primary Outcomes

Severity of physical symptoms and degree of psychological distress in chemotherapy-induced peripheral neuropathy.

Time Frame: Baseline, 6 weeks and 3 months.

The degree of change from baseline after the intervention (using the Treatment-Induced Neuropathy Assessment Scale (TNAS) to assess patients' CIPN-related physical symptom burden. The scale consists of 9 items, each scored from 0 to 10, with higher scores indicating a greater symptom burden. The Kessler Psychological Distress Scale (K10) was used to assess the level of psychological distress. The scale consists of 10 items, rated on a 5-point scale, with higher total scores indicating more severe psychological distress.)

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Nanjing Medical University
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Qingchun Geng

Student

Nanjing Medical University

Similar Trials